Immunomodulatory effect of CD200-positive human placenta-derived stem cells in the early phase of stroke

Stem cells derived from the human placenta offer therapeutic promise in reducing the brain inflammation associated with stroke. Recently, there has been considerable focus on treating the acute brain inflammation seen in stroke patients, and stem cells have gained attention as potential therapeutic agents due to their ability to suppress immune responses. Using a rat model of stroke, a team headed by Jisook Moon at CHA University in Gyeonggi-do, Korea, investigated how placental stem cells regulated the immune responses that occur following brain cell death and subsequent inflammation. The team found that CD200 (an anti-inflammatory factor) is a key molecule in the beneficial effects of stem cells in the early phase of stroke. The authors conclude that placental stem cells have great potential in effectively treating inflammation-related diseases.